http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 16 Jun 2026 08:33:28 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html <p>Entera Bio Ltd. (NASDAQ: ENTX) presented preclinical data for two pipeline candidates, EB612 and EB618, at ENDO 2026, the annual meeting of the Endocrine Society, on June 16, 2026. Both programs are being co-developed with OPKO Health Inc. (NASDAQ: OPK) on a 50/50 basis.</p> <p>EB612 is a long-acting PTH(1-34) analog formulated as an oral tablet for hypoparathyroidism. In a thyroparathyroidectomized rat model, daily dosing for seven days restored serum calcium and reduced phosphate to levels comparable to sham control animals. In a minipig model, a single oral dose reached peak plasma levels two to three hours post-dose, with drug detectable in http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html Tue, 16 Jun 2026 08:33:28 -0400 A.50203974 ENTX O.00028300 O.38505617 OPK http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html <p>Entera Bio Ltd. (NASDAQ: ENTX) presented preclinical data for two pipeline candidates, EB612 and EB618, at ENDO 2026, the annual meeting of the Endocrine Society, on June 16, 2026. Both programs are being co-developed with OPKO Health Inc. (NASDAQ: OPK) on a 50/50 basis.</p> <p>EB612 is a long-acting PTH(1-34) analog formulated as an oral tablet for hypoparathyroidism. In a thyroparathyroidectomized rat model, daily dosing for seven days restored serum calcium and reduced phosphate to levels comparable to sham control animals. In a minipig model, a single oral dose reached peak plasma levels two to three hours post-dose, with drug detectable in http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html Tue, 16 Jun 2026 08:33:28 -0400 A.50203974 ENTX O.00028300 O.38505617 OPK http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html <p>Entera Bio Ltd. (NASDAQ: ENTX) presented preclinical data for two pipeline candidates, EB612 and EB618, at ENDO 2026, the annual meeting of the Endocrine Society, on June 16, 2026. Both programs are being co-developed with OPKO Health Inc. (NASDAQ: OPK) on a 50/50 basis.</p> <p>EB612 is a long-acting PTH(1-34) analog formulated as an oral tablet for hypoparathyroidism. In a thyroparathyroidectomized rat model, daily dosing for seven days restored serum calcium and reduced phosphate to levels comparable to sham control animals. In a minipig model, a single oral dose reached peak plasma levels two to three hours post-dose, with drug detectable in http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html Tue, 16 Jun 2026 08:33:28 -0400 A.50203974 ENTX O.00028300 O.38505617 OPK http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html <p>Entera Bio Ltd. (NASDAQ: ENTX) presented preclinical data for two pipeline candidates, EB612 and EB618, at ENDO 2026, the annual meeting of the Endocrine Society, on June 16, 2026. Both programs are being co-developed with OPKO Health Inc. (NASDAQ: OPK) on a 50/50 basis.</p> <p>EB612 is a long-acting PTH(1-34) analog formulated as an oral tablet for hypoparathyroidism. In a thyroparathyroidectomized rat model, daily dosing for seven days restored serum calcium and reduced phosphate to levels comparable to sham control animals. In a minipig model, a single oral dose reached peak plasma levels two to three hours post-dose, with drug detectable in http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html Tue, 16 Jun 2026 08:33:28 -0400 A.50203974 ENTX O.00028300 O.38505617 OPK http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html <p>Entera Bio Ltd. (NASDAQ: ENTX) presented preclinical data for two pipeline candidates, EB612 and EB618, at ENDO 2026, the annual meeting of the Endocrine Society, on June 16, 2026. Both programs are being co-developed with OPKO Health Inc. (NASDAQ: OPK) on a 50/50 basis.</p> <p>EB612 is a long-acting PTH(1-34) analog formulated as an oral tablet for hypoparathyroidism. In a thyroparathyroidectomized rat model, daily dosing for seven days restored serum calcium and reduced phosphate to levels comparable to sham control animals. In a minipig model, a single oral dose reached peak plasma levels two to three hours post-dose, with drug detectable in http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html Tue, 16 Jun 2026 08:33:28 -0400 A.50203974 ENTX O.00028300 O.38505617 OPK http://www.streetinsider.com/Press+Releases/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html <p align="center"><i>EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026</i></p> <p align="center"><i>EB618, a first-in-class dual GLP-1/glucagon oral receptor agonist (oxyntomodulin) for obesity and metabolic disorders, showed dose-proportional pharmacokinetics and a robust effect on blood glucose in non-human primates</i></p> <p align="justify">TEL AVIV, June 16, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”), a leader in the development of oral peptides, reported preclinical data at ENDO 2026, the annual meeting of the Endocrine Society, for its EB612 http://www.streetinsider.com/Press+Releases/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html Tue, 16 Jun 2026 08:33:00 -0400 A.50203974 ENTX O.00028300 O.38505617 http://www.streetinsider.com/Press+Releases/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html <p align="center"><i>EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026</i></p> <p align="center"><i>EB618, a first-in-class dual GLP-1/glucagon oral receptor agonist (oxyntomodulin) for obesity and metabolic disorders, showed dose-proportional pharmacokinetics and a robust effect on blood glucose in non-human primates</i></p> <p align="justify">TEL AVIV, June 16, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”), a leader in the development of oral peptides, reported preclinical data at ENDO 2026, the annual meeting of the Endocrine Society, for its EB612 http://www.streetinsider.com/Press+Releases/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html Tue, 16 Jun 2026 08:33:00 -0400 A.50203974 ENTX O.00028300 O.38505617 http://www.streetinsider.com/Press+Releases/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html <p align="center"><i>EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026</i></p> <p align="center"><i>EB618, a first-in-class dual GLP-1/glucagon oral receptor agonist (oxyntomodulin) for obesity and metabolic disorders, showed dose-proportional pharmacokinetics and a robust effect on blood glucose in non-human primates</i></p> <p align="justify">TEL AVIV, June 16, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”), a leader in the development of oral peptides, reported preclinical data at ENDO 2026, the annual meeting of the Endocrine Society, for its EB612 http://www.streetinsider.com/Press+Releases/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html Tue, 16 Jun 2026 08:33:00 -0400 A.50203974 ENTX O.00028300 O.38505617 http://www.streetinsider.com/Press+Releases/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html <p align="center"><i>EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026</i></p> <p align="center"><i>EB618, a first-in-class dual GLP-1/glucagon oral receptor agonist (oxyntomodulin) for obesity and metabolic disorders, showed dose-proportional pharmacokinetics and a robust effect on blood glucose in non-human primates</i></p> <p align="justify">TEL AVIV, June 16, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”), a leader in the development of oral peptides, reported preclinical data at ENDO 2026, the annual meeting of the Endocrine Society, for its EB612 http://www.streetinsider.com/Press+Releases/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html Tue, 16 Jun 2026 08:33:00 -0400 A.50203974 ENTX O.00028300 O.38505617 http://www.streetinsider.com/Globe+Newswire/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html <p align="center"><i>EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026</i></p> <p align="center"><i>EB618, a first-in-class dual GLP-1/glucagon oral receptor agonist (oxyntomodulin) for obesity and metabolic disorders, showed dose-proportional pharmacokinetics and a robust effect on blood glucose in non-human primates</i></p> <p align="justify">TEL AVIV, June 16, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”), a leader in the development of oral peptides, reported preclinical data at ENDO 2026, the annual meeting of the Endocrine Society, for its EB612 http://www.streetinsider.com/Globe+Newswire/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html Tue, 16 Jun 2026 08:33:00 -0400 A.50203974 ENTX O.00028300 O.38505617 http://www.streetinsider.com/Globe+Newswire/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html <p align="center"><i>EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026</i></p> <p align="center"><i>EB618, a first-in-class dual GLP-1/glucagon oral receptor agonist (oxyntomodulin) for obesity and metabolic disorders, showed dose-proportional pharmacokinetics and a robust effect on blood glucose in non-human primates</i></p> <p align="justify">TEL AVIV, June 16, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”), a leader in the development of oral peptides, reported preclinical data at ENDO 2026, the annual meeting of the Endocrine Society, for its EB612 http://www.streetinsider.com/Globe+Newswire/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html Tue, 16 Jun 2026 08:33:00 -0400 A.50203974 ENTX O.00028300 O.38505617 http://www.streetinsider.com/Globe+Newswire/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html <p align="center"><i>EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026</i></p> <p align="center"><i>EB618, a first-in-class dual GLP-1/glucagon oral receptor agonist (oxyntomodulin) for obesity and metabolic disorders, showed dose-proportional pharmacokinetics and a robust effect on blood glucose in non-human primates</i></p> <p align="justify">TEL AVIV, June 16, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”), a leader in the development of oral peptides, reported preclinical data at ENDO 2026, the annual meeting of the Endocrine Society, for its EB612 http://www.streetinsider.com/Globe+Newswire/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html Tue, 16 Jun 2026 08:33:00 -0400 A.50203974 ENTX O.00028300 O.38505617 http://www.streetinsider.com/Globe+Newswire/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html <p align="center"><i>EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026</i></p> <p align="center"><i>EB618, a first-in-class dual GLP-1/glucagon oral receptor agonist (oxyntomodulin) for obesity and metabolic disorders, showed dose-proportional pharmacokinetics and a robust effect on blood glucose in non-human primates</i></p> <p align="justify">TEL AVIV, June 16, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”), a leader in the development of oral peptides, reported preclinical data at ENDO 2026, the annual meeting of the Endocrine Society, for its EB612 http://www.streetinsider.com/Globe+Newswire/Entera+Reports+Robust+Preclinical+Data+for+EB612+%28Oral+LA-PTH%281-34%29%29+for+Hypoparathyroidism+and+EB618+%28Oral+GLP-1Glucagon%29+for+Obesity+at+ENDO+2026/26651076.html Tue, 16 Jun 2026 08:33:00 -0400 A.50203974 ENTX O.00028300 O.38505617 http://www.streetinsider.com/Corporate+News/Entera+reports+comparable+results+for+single-tablet+EB613+versus+injection/26644842.html <p>Entera Bio Ltd. (NASDAQ: ENTX) reported Phase 1 clinical data showing its single-tablet oral EB613 achieved comparable pharmacokinetic and pharmacodynamic profiles to both its multi-tablet version and Forteo injection for osteoporosis treatment.</p><p>The study involved 15 healthy participants who received single-tablet EB613, multi-tablet EB613, and subcutaneous Forteo at doses ranging from 1 mg to 3 mg. Results showed the single tablet demonstrated similar maximum concentration, time to maximum concentration, and total systemic exposure compared to the multi-tablet formulation.</p><p>Both oral EB613 formulations showed comparable area under the curve to Forteo, with a slightly shorter duration of exposure consistent with prior Phase 1 http://www.streetinsider.com/Corporate+News/Entera+reports+comparable+results+for+single-tablet+EB613+versus+injection/26644842.html Mon, 15 Jun 2026 08:45:39 -0400 ENTX http://www.streetinsider.com/FDA/Entera+reports+comparable+results+for+single-tablet+EB613+versus+injection/26644842.html <p>Entera Bio Ltd. (NASDAQ: ENTX) reported Phase 1 clinical data showing its single-tablet oral EB613 achieved comparable pharmacokinetic and pharmacodynamic profiles to both its multi-tablet version and Forteo injection for osteoporosis treatment.</p><p>The study involved 15 healthy participants who received single-tablet EB613, multi-tablet EB613, and subcutaneous Forteo at doses ranging from 1 mg to 3 mg. Results showed the single tablet demonstrated similar maximum concentration, time to maximum concentration, and total systemic exposure compared to the multi-tablet formulation.</p><p>Both oral EB613 formulations showed comparable area under the curve to Forteo, with a slightly shorter duration of exposure consistent with prior Phase 1 http://www.streetinsider.com/FDA/Entera+reports+comparable+results+for+single-tablet+EB613+versus+injection/26644842.html Mon, 15 Jun 2026 08:45:39 -0400 ENTX http://www.streetinsider.com/Press+Releases/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29+/26644835.html <p align="center"><i>The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 </i></p> <p align="center"><i>Single tablet EB613 achieved a comparable PK/PD profile to Forteo® and multi-tablet EB613, which was evaluated in Entera’s Phase 2 study in postmenopausal women with osteoporosis and low bone mass </i></p> <p align="center"><i>This major scientific achievement supports advancing single tablet EB613 into Entera’s planned Phase 3 study of EB613 in postmenopausal women with osteoporosis</i></p> <p align="justify">TEL AVIV, June 15, 2026 (GLOBE NEWSWIRE) -- Entera http://www.streetinsider.com/Press+Releases/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29+/26644835.html Mon, 15 Jun 2026 08:45:00 -0400 ENTX http://www.streetinsider.com/Globe+Newswire/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29+/26644835.html <p align="center"><i>The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 </i></p> <p align="center"><i>Single tablet EB613 achieved a comparable PK/PD profile to Forteo® and multi-tablet EB613, which was evaluated in Entera’s Phase 2 study in postmenopausal women with osteoporosis and low bone mass </i></p> <p align="center"><i>This major scientific achievement supports advancing single tablet EB613 into Entera’s planned Phase 3 study of EB613 in postmenopausal women with osteoporosis</i></p> <p align="justify">TEL AVIV, June 15, 2026 (GLOBE NEWSWIRE) -- Entera http://www.streetinsider.com/Globe+Newswire/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29+/26644835.html Mon, 15 Jun 2026 08:45:00 -0400 ENTX http://www.streetinsider.com/Press+Releases/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html <p align="center"><i>The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 </i></p> <p align="center"><i>Single tablet EB613 achieved a comparable PK/PD profile to Forteo® and multi-tablet EB613, which was evaluated in Entera’s Phase 2 study in postmenopausal women with osteoporosis and low bone mass </i></p> <p align="center"><i>This major scientific achievement supports advancing single tablet EB613 into Entera’s planned Phase 3 study of EB613 in postmenopausal women with osteoporosis</i></p> <p align="justify">TEL AVIV, June 15, 2026 (GLOBE NEWSWIRE) -- Entera http://www.streetinsider.com/Press+Releases/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html Mon, 15 Jun 2026 08:45:00 -0400 A.50203974 ENTX O.00028300 O.38505617 http://www.streetinsider.com/Press+Releases/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html <p align="center"><i>The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 </i></p> <p align="center"><i>Single tablet EB613 achieved a comparable PK/PD profile to Forteo® and multi-tablet EB613, which was evaluated in Entera’s Phase 2 study in postmenopausal women with osteoporosis and low bone mass </i></p> <p align="center"><i>This major scientific achievement supports advancing single tablet EB613 into Entera’s planned Phase 3 study of EB613 in postmenopausal women with osteoporosis</i></p> <p align="justify">TEL AVIV, June 15, 2026 (GLOBE NEWSWIRE) -- Entera http://www.streetinsider.com/Press+Releases/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html Mon, 15 Jun 2026 08:45:00 -0400 A.50203974 ENTX O.00028300 O.38505617 http://www.streetinsider.com/Press+Releases/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html <p align="center"><i>The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 </i></p> <p align="center"><i>Single tablet EB613 achieved a comparable PK/PD profile to Forteo® and multi-tablet EB613, which was evaluated in Entera’s Phase 2 study in postmenopausal women with osteoporosis and low bone mass </i></p> <p align="center"><i>This major scientific achievement supports advancing single tablet EB613 into Entera’s planned Phase 3 study of EB613 in postmenopausal women with osteoporosis</i></p> <p align="justify">TEL AVIV, June 15, 2026 (GLOBE NEWSWIRE) -- Entera http://www.streetinsider.com/Press+Releases/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html Mon, 15 Jun 2026 08:45:00 -0400 A.50203974 ENTX O.00028300 O.38505617 http://www.streetinsider.com/Press+Releases/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html <p align="center"><i>The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 </i></p> <p align="center"><i>Single tablet EB613 achieved a comparable PK/PD profile to Forteo® and multi-tablet EB613, which was evaluated in Entera’s Phase 2 study in postmenopausal women with osteoporosis and low bone mass </i></p> <p align="center"><i>This major scientific achievement supports advancing single tablet EB613 into Entera’s planned Phase 3 study of EB613 in postmenopausal women with osteoporosis</i></p> <p align="justify">TEL AVIV, June 15, 2026 (GLOBE NEWSWIRE) -- Entera http://www.streetinsider.com/Press+Releases/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html Mon, 15 Jun 2026 08:45:00 -0400 A.50203974 ENTX O.00028300 O.38505617 http://www.streetinsider.com/Globe+Newswire/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html <p align="center"><i>The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 </i></p> <p align="center"><i>Single tablet EB613 achieved a comparable PK/PD profile to Forteo® and multi-tablet EB613, which was evaluated in Entera’s Phase 2 study in postmenopausal women with osteoporosis and low bone mass </i></p> <p align="center"><i>This major scientific achievement supports advancing single tablet EB613 into Entera’s planned Phase 3 study of EB613 in postmenopausal women with osteoporosis</i></p> <p align="justify">TEL AVIV, June 15, 2026 (GLOBE NEWSWIRE) -- Entera http://www.streetinsider.com/Globe+Newswire/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html Mon, 15 Jun 2026 08:45:00 -0400 A.50203974 ENTX O.00028300 O.38505617 http://www.streetinsider.com/Globe+Newswire/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html <p align="center"><i>The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 </i></p> <p align="center"><i>Single tablet EB613 achieved a comparable PK/PD profile to Forteo® and multi-tablet EB613, which was evaluated in Entera’s Phase 2 study in postmenopausal women with osteoporosis and low bone mass </i></p> <p align="center"><i>This major scientific achievement supports advancing single tablet EB613 into Entera’s planned Phase 3 study of EB613 in postmenopausal women with osteoporosis</i></p> <p align="justify">TEL AVIV, June 15, 2026 (GLOBE NEWSWIRE) -- Entera http://www.streetinsider.com/Globe+Newswire/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html Mon, 15 Jun 2026 08:45:00 -0400 A.50203974 ENTX O.00028300 O.38505617 http://www.streetinsider.com/Globe+Newswire/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html <p align="center"><i>The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 </i></p> <p align="center"><i>Single tablet EB613 achieved a comparable PK/PD profile to Forteo® and multi-tablet EB613, which was evaluated in Entera’s Phase 2 study in postmenopausal women with osteoporosis and low bone mass </i></p> <p align="center"><i>This major scientific achievement supports advancing single tablet EB613 into Entera’s planned Phase 3 study of EB613 in postmenopausal women with osteoporosis</i></p> <p align="justify">TEL AVIV, June 15, 2026 (GLOBE NEWSWIRE) -- Entera http://www.streetinsider.com/Globe+Newswire/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html Mon, 15 Jun 2026 08:45:00 -0400 A.50203974 ENTX O.00028300 O.38505617 http://www.streetinsider.com/Globe+Newswire/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html <p align="center"><i>The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 </i></p> <p align="center"><i>Single tablet EB613 achieved a comparable PK/PD profile to Forteo® and multi-tablet EB613, which was evaluated in Entera’s Phase 2 study in postmenopausal women with osteoporosis and low bone mass </i></p> <p align="center"><i>This major scientific achievement supports advancing single tablet EB613 into Entera’s planned Phase 3 study of EB613 in postmenopausal women with osteoporosis</i></p> <p align="justify">TEL AVIV, June 15, 2026 (GLOBE NEWSWIRE) -- Entera http://www.streetinsider.com/Globe+Newswire/ENDO+2026+Oral+Presentation+Highlights+Comparative+Clinical+Data+for+Entera%E2%80%99s+Breakthrough+Single+Tablet+EB613+%28First-in-Class+Oral+PTH%281-34%29+Anabolic+for+Osteoporosis%29/26644841.html Mon, 15 Jun 2026 08:45:00 -0400 A.50203974 ENTX O.00028300 O.38505617